Nimotuzumab for EGFR-high pancreatic neuroendocrine tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 study tests nimotuzumab (a drug that targets EGFR) in people with pancreatic neuroendocrine tumors that can’t be cured by surgery or radiation. It aims to slow tumor growth in patients whose tumor shows high EGFR levels and has recently worsened on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic neuroendocrine tumor that is unresectable or has spread (metastatic).
- Your tumor tissue shows high EGFR (you must have stored tumor sample available).
- Your disease has gotten worse on scans within the last 12 months.
- You have at least one measurable tumor spot on imaging that can be tracked.
- You are age 18 or older and well enough to do usual activities (ECOG less than 2).
- You have adequate blood and organ function (specific lab and kidney/liver thresholds) and can join visits and tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial uses a lab-grown model of your tumor (called an organoid) to test which drugs might work best for you. It is for people with advanced pancreatic neuroendocrine tumors who cannot have surgery.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests combining a targeted drug (nimotuzumab) with two chemotherapy drugs (nab-paclitaxel and gemcitabine) before and after surgery for pancreatic cancer that can be surgically removed but has high-risk features or is borderline resectable. The goal is to see if this approach improves outcomes.
Hear when a new Pancreatic Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.